



Receipt

# PATENT APPLICATION

Attorney Docket No.: A-68893/DJB/DAV

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

David A. ESTELL, et al.

Serial No.: 09/500,135

Filed: February 8, 2000

For: PROTEINS PRODUCING AN  
ALTERED IMMUNOGENIC  
RESPONSE AND METHODS  
OF MAKING AND USING THE  
SAME.

Examiner: UNKNOWN

Group Art Unit: 1643

### CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Assistant Secretary and Commissioner of Patents and Trademarks, Office of Initial Patent Examination's Customer Service Center, Washington, D.C. 20231 on 6/12/00

Signature

Judy J. Wilson

RECEIVED

AUG 02 2000

TECH CENTER 1000 2000

## REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Assistant Secretary and  
Commissioner of Patents and Trademarks  
Office of Initial Patent Examination's  
Customer Service Center  
Washington, D.C. 20231

Sir:

Appended hereto is a copy of the Official Filing Receipt for the above-identified patent application with the errors indicated in red.

In the Applicant(s) portion of the receipt, before "Estell," and after "David", please insert --A.--.

In the Applicant(s) portion of the receipt, before "Harding," and after "Fiona", please insert --A.--.

**FII F COPY**

<b>SERIAL NUMBER</b> 09/500,135	<b>FILING DATE</b> 02/08/2000 <b>RULE</b> —	<b>CLASS</b> 435	<b>GROUP ART UNIT</b> 1643	<b>ATTORNEY DOCKET NO.</b> A-68893/DJB/DAV
------------------------------------	---	---------------------	-------------------------------	---

David A. Estell, San Mateo, CA ;  
Fiona A. Harding, Santa Clara, CA ;

\*\*\* CONTINUING DATA \*\*\*

THIS APPLICATION IS A CIP OF 09/060,872 04/15/1998

**\*\* FOREIGN APPLICATIONS \*\*\*\*\***

IF REQUIRED, FOREIGN FILING LICENSE  
GRANTED \*\* 03/14/2000

Foreign Priority claimed

☐ yes ☒ no

35 USC 119 (a-d) conditions met

☐ yes ☒ no ☐ Met after

Verified and  
Acknowledged

Allowance  
Examiner's Signature David A. Schneider Initials

STATE OR  
COUNTRY  
CA

**SHEETS**  
**DRAWING**  
27

**TOTAL  
CLAIMS**  
28

INDEPENDENT  
CLAIMS  
4

**ADDRESS**

Flehr Hohbach Test Albritton & Herbert LLP  
Four Embarcadero Center Suite 3400  
San Francisco ,CA 94111-4187

**TITLE**

## Proteins producing an altered immunogenic response and methods of making and using the same

FILING FEE  
RECEIVED  
1042

FEES: Authority has been given in Paper  
No. \_\_\_\_\_ to charge/credit DEPOSIT ACCOUNT  
No. \_\_\_\_\_ for following:

- ☐ All Fees
- ☐ 1.16 Fees ( Filing )
- ☐ 1.17 Fees ( Processing Ext. of time )
- ☐ 1.18 Fees ( Issue )
- ☐ Other \_\_\_\_\_
- ☐ Credit

The Applicant(s) portion of the receipt will then correctly read as follows:

David A. Estell, San Mateo, CA;


Fiona A. Harding, Santa Clara, CA;

Because the error was caused by the Patent Office, it is believed that no fee is necessary. However, if this belief is in error, the Commissioner is authorized to charge any fee which may be required, or credit any overpayment to Deposit Account No. 06-1300 (Our Order No. A-68893/DJB/DAV).

Respectfully submitted,

FLEHR HOHBACH TEST  
ALBRITTON & HERBERT LLP

Date: 6-13-00

  
\_\_\_\_\_  
Dolly A. Vance  
Reg No. 39,054


Four Embarcadero Center  
Suite 3400  
San Francisco, CA 94111-4187  
Telephone: (415) 781-1989

1021384

## FILING RECEIPT



\*OC000000005144553\*

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark OfficeAddress: ASSISTANT SECRETARY AND  
COMMISSIONER OF PATENT AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/500,135	02/08/2000	1643	1042	A-68893/DJB/DAV	27	28	4

Flehr Hohbach Test Albritton & Herbert LLP  
Four Embarcadero Center Suite 3400  
San Francisco, CA 94111-4187

Date Mailed: 05/30/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

## Applicant(s)

A.  
David Estell, San Mateo, CA ;  
Fiona Harding, Santa Clara, CA ;  
A.

RECEIVED

AUG 02 2000

TECH CENTER 1600/2900

## Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/060,872 04/15/1998

## Foreign Applications

If Required, Foreign Filing License Granted 03/14/2000

—

## Title

Proteins producing an altered immunogenic response and methods of making and using the same

## Preliminary Class

435

Data entry by : DAVENPORT, BOBBIE

Team : OIPE

Date: 05/30/2000





**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231